<VariationArchive VariationID="428458" VariationName="NM_000251.3(MSH2):c.989dup (p.Asn331fs)" VariationType="Duplication" Accession="VCV000428458" Version="7" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-06-23" DateCreated="2017-06-25" MostRecentSubmission="2024-05-01">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="419348" VariationID="428458">
      <GeneList>
        <Gene Symbol="MSH2" FullName="mutS homolog 2" GeneID="4436" HGNC_ID="HGNC:7325" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>2p21-16.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="47403067" stop="47709830" display_start="47403067" display_stop="47709830" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="47630205" stop="47710366" display_start="47630205" display_stop="47710366" Strand="+" />
          </Location>
          <OMIM>609309</OMIM>
          <Haploinsufficiency last_evaluated="2021-10-13" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MSH2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-10-13" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=MSH2">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000251.3(MSH2):c.989dup (p.Asn331fs)</Name>
      <CanonicalSPDI>NC_000002.12:47416341:T:TT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>2p21</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="47416341" stop="47416342" display_start="47416341" display_stop="47416342" variantLength="1" positionVCF="47416341" referenceAlleleVCF="C" alternateAlleleVCF="CT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="47643480" stop="47643481" display_start="47643480" display_stop="47643481" variantLength="1" positionVCF="47643480" referenceAlleleVCF="C" alternateAlleleVCF="CT" />
      </Location>
      <ProteinChange>N265fs</ProteinChange>
      <ProteinChange>N331fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.47643481dup" Assembly="GRCh37">
            <Expression>NC_000002.11:g.47643481dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.47416342dup" Assembly="GRCh38">
            <Expression>NC_000002.12:g.47416342dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007110.2" sequenceAccession="NG_007110" sequenceVersion="2" change="g.18219dup">
            <Expression>NG_007110.2:g.18219dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000251.3" sequenceAccession="NM_000251" sequenceVersion="3" change="c.989dup" MANESelect="true">
            <Expression>NM_000251.3:c.989dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000242.1" sequenceAccession="NP_000242" sequenceVersion="1" change="p.Asn331fs">
            <Expression>NP_000242.1:p.Asn331fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001258281.1" sequenceAccession="NM_001258281" sequenceVersion="1" change="c.791dup">
            <Expression>NM_001258281.1:c.791dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001245210.1" sequenceAccession="NP_001245210" sequenceVersion="1" change="p.Asn265fs">
            <Expression>NP_001245210.1:p.Asn265fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_218" sequenceAccession="LRG_218">
            <Expression>LRG_218:g.18219dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA645369196" DB="ClinGen" />
        <XRef Type="rs" ID="1114167813" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000251.3(MSH2):c.989dup (p.Asn331fs) AND Hereditary cancer-predisposing syndrome" Accession="RCV000491473" Version="3">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2016-01-06" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000251.3(MSH2):c.989dup (p.Asn331fs) AND Lynch syndrome 1" Accession="RCV003449342" Version="1">
        <ClassifiedConditionList TraitSetID="451">
          <ClassifiedCondition DB="MedGen" ID="C2936783">Lynch syndrome 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-07-28" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000251.3(MSH2):c.989dup (p.Asn331fs) AND Lynch syndrome" Accession="RCV004017646" Version="2">
        <ClassifiedConditionList TraitSetID="8777">
          <ClassifiedCondition DB="MedGen" ID="C4552100">Lynch syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-10-28" SubmissionCount="1">Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-07-28" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2017-06-25" MostRecentSubmission="2024-05-01">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic/Likely pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">25006859</ID>
        </Citation>
        <DescriptionHistory Dated="2024-04-20">
          <Description>Pathogenic</Description>
        </DescriptionHistory>
        <ConditionList>
          <TraitSet ID="451" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2582" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hereditary non-polyposis colorectal cancer, type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Lynch syndrome I</ElementValue>
                <Citation Type="general" Abbrev="Vasen et al., 2007">
                  <ID Source="pmc">2740877</ID>
                </Citation>
                <XRef ID="Colorectal+Cancer%2C+Hereditary+Nonpolyposis%2C+Type+1/1748" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Colorectal cancer, hereditary, nonpolyposis, type 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">COLON CANCER, FAMILIAL NONPOLYPOSIS, TYPE 1</ElementValue>
                <XRef Type="MIM" ID="120435" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Lynch syndrome 1</ElementValue>
                <XRef ID="MONDO:0007356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">MSH2-Related Lynch Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">MSH2-Related Hereditary Non-Polyposis Colon Cancer</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FCC1</ElementValue>
                <XRef Type="MIM" ID="120435" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">HNPCC1</ElementValue>
                <XRef Type="MIM" ID="120435" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15052" />
                <XRef ID="15052" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000512645" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501399" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000510683" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507864" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000595970" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000518997" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514729" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569406" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501401" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000518999" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate. Cancer risks and age of onset vary depending on the associated gene. Several other cancer types have been reported to occur in individuals with Lynch syndrome (e.g., breast, sarcomas, adrenocortical carcinoma). However, the data are not sufficient to demonstrate that the risk of developing these cancers is increased in individuals with Lynch syndrome.</Attribute>
                <XRef ID="NBK1211" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301390</ID>
                <ID Source="BookShelf">NBK1211</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGAPP, 2009">
                <ID Source="pmc">2743612</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="Vasen et al., 2007">
                <ID Source="pmc">2740877</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCRS, 2001">
                <ID Source="PubMed">11598466</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2010">
                <ID Source="pmc">2987434</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="AMA/NCHPEG, 2012">
                <URL>http://www.nchpeg.org/documents/crc/11-0456%20Fact%20sheets%20(MSI%20and%20IHC%20testing).pdf</URL>
              </Citation>
              <Citation Type="practice guideline" Abbrev="SGO, 2014">
                <URL>https://www.sgo.org/clinical-practice/guidelines/screening-for-lynch-syndrome-in-endometrial-cancer</URL>
                <CitationText>Society of Gynecologic Oncology (SGO) Clinical Practice Statement: Screening for Lynch Syndrome in Endometrial Cancer</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="MSTF, 2014">
                <ID Source="PubMed">25070057</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2013">
                <ID Source="pmc">3585492</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO/ESMO, 2015">
                <ID Source="PubMed">25452455</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2014">
                <ID Source="PubMed">24310308</ID>
              </Citation>
              <Citation Type="general" Abbrev="Mork et al., 2015">
                <ID Source="PubMed">25711197</ID>
              </Citation>
              <Citation Type="general" Abbrev="Dutch SCG, 2013">
                <ID Source="PubMed">23535968</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACG, 2015">
                <ID Source="PubMed">25645574</ID>
              </Citation>
              <Citation Type="general" Abbrev="Mallorca group, 2013">
                <ID Source="PubMed">23408351</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC/CCA-ICC, 2012">
                <ID Source="PubMed">22167527</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer, 2024</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Genetics of Colorectal Cancer">
                <ID Source="PubMed">26389505</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2020">
                <ID Source="PubMed">31672839</ID>
                <ID Source="pmc">7295005</ID>
              </Citation>
              <Citation Type="general" Abbrev="EHTG/ESCP, 2021">
                <ID Source="PubMed">34043773</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Colon-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics Family History ACT Sheet, Colon Cancer (Asymptomatic), 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Lynch-Syndrome.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, MLH1, MSH2, MSH6, PMS2, EPCAM Pathogenic Variants, Lynch Syndrome (Hereditary Non-polyposis Colon Cancer [HNPCC]), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2021">
                <URL>https://www.nice.org.uk/guidance/ng151</URL>
                <CitationText>UK NICE Guideline NG151, Colorectal cancer, 2021</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2020">
                <URL>https://www.nice.org.uk/guidance/dg42</URL>
                <CitationText>UK NICE Diagnostics Guidance DG42, Testing strategies for Lynch syndrome in people with endometrial cancer, 2020</CitationText>
              </Citation>
              <XRef ID="144" DB="Orphanet" />
              <XRef ID="C2936783" DB="MedGen" />
              <XRef ID="MONDO:0007356" DB="MONDO" />
              <XRef Type="MIM" ID="120435" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="8777" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="14688" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Lynch syndrome</ElementValue>
                <XRef ID="2622" DB="GeneTests" />
                <XRef ID="Hereditary+Non-Polyposis+Colorectal+Cancer+%28HNPCC%29/3371" DB="Genetic Alliance" />
                <XRef ID="MONDO:0005835" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="9905" />
                <XRef ID="9905" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551463" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000316595" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552440" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591173" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000322202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520394" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528915" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551459" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520868" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558908" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520392" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000515821" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000321105" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000515534" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522224" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512828" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520080" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569958" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512403" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000518999" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520871" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552184" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000515774" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528930" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528534" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000519150" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527984" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591263" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520872" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520030" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561860" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551464" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562151" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522225" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000332519" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528914" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325623" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530028" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528529" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522559" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520870" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527983" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520869" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000519254" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000568362" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527981" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522278" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000529017" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000518997" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000568365" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520865" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552183" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551461" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Lynch syndrome is characterized by an increased risk for colorectal cancer (CRC) and cancers of the endometrium, ovary, stomach, small bowel, urinary tract, biliary tract, brain (usually glioblastoma), skin (sebaceous adenomas, sebaceous carcinomas, and keratoacanthomas), pancreas, and prostate. Cancer risks and age of onset vary depending on the associated gene. Several other cancer types have been reported to occur in individuals with Lynch syndrome (e.g., breast, sarcomas, adrenocortical carcinoma). However, the data are not sufficient to demonstrate that the risk of developing these cancers is increased in individuals with Lynch syndrome.</Attribute>
                <XRef ID="NBK1211" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301390</ID>
                <ID Source="BookShelf">NBK1211</ID>
              </Citation>
              <Citation Type="general" Abbrev="EGAPP, 2009">
                <ID Source="pmc">2743612</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCRS, 2001">
                <ID Source="PubMed">11598466</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="AMA/NCHPEG, 2012">
                <URL>http://www.nchpeg.org/documents/crc/11-0456%20Fact%20sheets%20(MSI%20and%20IHC%20testing).pdf</URL>
              </Citation>
              <Citation Type="practice guideline" Abbrev="SGO, 2014">
                <URL>https://www.sgo.org/clinical-practice/guidelines/screening-for-lynch-syndrome-in-endometrial-cancer</URL>
                <CitationText>Society of Gynecologic Oncology (SGO) Clinical Practice Statement: Screening for Lynch Syndrome in Endometrial Cancer</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="MSTF, 2014">
                <ID Source="PubMed">25070057</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2013">
                <ID Source="pmc">3585492</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO/ESMO, 2015">
                <ID Source="PubMed">25452455</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2014">
                <ID Source="PubMed">24310308</ID>
              </Citation>
              <Citation Type="general" Abbrev="Mork et al., 2015">
                <ID Source="PubMed">25711197</ID>
              </Citation>
              <Citation Type="general" Abbrev="Dutch SCG, 2013">
                <ID Source="PubMed">23535968</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACG, 2015">
                <ID Source="PubMed">25645574</ID>
              </Citation>
              <Citation Type="general" Abbrev="Mallorca group, 2013">
                <ID Source="PubMed">23408351</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2024">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer, 2024</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Genetics of Colorectal Cancer">
                <ID Source="PubMed">26389505</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2020">
                <ID Source="PubMed">31672839</ID>
                <ID Source="pmc">7295005</ID>
              </Citation>
              <Citation Type="general" Abbrev="EHTG/ESCP, 2021">
                <ID Source="PubMed">34043773</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Goldberg et al, 2019">
                <ID Source="PubMed">31302137</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Colon-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics Family History ACT Sheet, Colon Cancer (Asymptomatic), 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2021">
                <URL>https://www.nice.org.uk/guidance/ng151</URL>
                <CitationText>UK NICE Guideline NG151, Colorectal cancer, 2021</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2020">
                <URL>https://www.nice.org.uk/guidance/dg42</URL>
                <CitationText>UK NICE Diagnostics Guidance DG42, Testing strategies for Lynch syndrome in people with endometrial cancer, 2020</CitationText>
              </Citation>
              <XRef ID="144" DB="Orphanet" />
              <XRef ID="C4552100" DB="MedGen" />
              <XRef ID="MONDO:0005835" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7825568" SubmissionDate="2023-12-21" DateLastUpdated="2023-12-24" DateCreated="2023-12-24">
        <ClinVarSubmissionID localKey="100448065|OMIM:120435" />
        <ClinVarAccession Accession="SCV004187002" DateUpdated="2023-12-24" DateCreated="2023-12-24" Type="SCV" Version="1" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-07-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Autosomal Dominant, Autosomal Recessive and X-Linked Classification Criteria (2023)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/8ufcwsf2/myriad_genetics_classification_criteria_2023.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MSH2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="hg19" Chr="2" alternateAllele="TT" referenceAllele="T" start="47643481" stop="47643481" />
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">100448065</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="120435" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14104645</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9056221" SubmissionDate="2024-04-19" DateLastUpdated="2024-04-20" DateCreated="2024-04-20">
        <ClinVarSubmissionID localKey="102174359|Orphanet:ORPHA144" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV004848539" DateUpdated="2024-04-20" DateCreated="2024-04-20" Type="SCV" Version="1" SubmitterName="Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine" OrgID="21766" OrganizationCategory="laboratory" OrgAbbreviation="LMM" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-10-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely Pathogenic</GermlineClassification>
          <Comment>The p.Asn331GlufsX2 variant in MSH2 has been reported in 1 individual with an MSH2-associated cancer (Everett 2014 PMID: 25006859). It was also reported by other clinical laboratories in ClinVar (Variation ID: 428458) and was absent from large population studies. This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 331 and leads to a premature termination codon 2 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the MSH2 gene is an established disease mechanism in autosomal dominant Lynch syndrome. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal dominant Lynch syndrome. ACMG/AMP Criteria applied: PVS1, PM2_Supporting.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MSH2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000251.3:exon 6</GeneLocation>
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000002.12:g.47416342_47416343insT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA144" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14389831</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1130184" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2017-06-25">
        <ClinVarSubmissionID localKey="a61695|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000580429" DateUpdated="2024-05-01" DateCreated="2017-06-25" Type="SCV" Version="6" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-01-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">25006859</ID>
          </Citation>
          <Comment>The c.989dupT pathogenic mutation, located in coding exon 6 of the MSH2 gene, results from a duplication of T at nucleotide position 989, causing a translational frameshift with a predicted alternate stop codon. This alteration was previously identified in one individual who was diagnosed with endometrial cancer at age 42 and a sebaceous adenoma at age 66. This individual's mother was diagnosed with endometrial cancer at age 50 and bladder cancer at age 91 (Everett JN, JAMA Dermatol 2014 Dec; 150(12):1315-21). In addition to the clinical history presented in the literature, since frameshifts are typically deleterious in nature, this alteration is interpreted as a disease-causing mutation (ACMG Recommendations for Standards for Interpretation and Reporting of Sequence Variations. Revision 2007. Genet Med. 2008;10:294).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="MSH2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000251.1:c.989dupT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
          <SubmissionName>NonExomeUpdate_081220AmbryReport</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1130184" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9056221" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA144" MappingRef="Orphanet">
        <MedGen CUI="C4552100" Name="Lynch syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7825568" TraitType="Disease" MappingType="XRef" MappingValue="120435" MappingRef="OMIM">
        <MedGen CUI="C2936783" Name="Lynch syndrome 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

